[go: up one dir, main page]

EA200200313A1 - Применение доцетаксела для лечения печеночно-клеточного рака - Google Patents

Применение доцетаксела для лечения печеночно-клеточного рака

Info

Publication number
EA200200313A1
EA200200313A1 EA200200313A EA200200313A EA200200313A1 EA 200200313 A1 EA200200313 A1 EA 200200313A1 EA 200200313 A EA200200313 A EA 200200313A EA 200200313 A EA200200313 A EA 200200313A EA 200200313 A1 EA200200313 A1 EA 200200313A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
docetexela
hepatic
application
cellular cancer
Prior art date
Application number
EA200200313A
Other languages
English (en)
Other versions
EA004804B1 (ru
Inventor
Чинь-Вэнь Чи
Хэн-Лян Линь
Цзун-Юнь Лю
Вин-Ию Луи
Гар-Ян Чао
Original Assignee
Авентис Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фарма С.А. filed Critical Авентис Фарма С.А.
Publication of EA200200313A1 publication Critical patent/EA200200313A1/ru
Publication of EA004804B1 publication Critical patent/EA004804B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение основано на открытии того факта, что доцетаксел является значительно более активным в отношении клеток печеночно-клеточного рака, чем паклитаксел, в концентрациях до 1 мкМ. Соответственно оно предлагает применение доцетаксела или его гидрата в производстве лекарственных средств для применения при лечении печеночно-клеточного рака.Отчет о международном поиске был опубликован 2001.09.20.
EA200200313A 1999-08-31 2000-08-29 Применение доцетаксела для лечения печеночно-клеточного рака EA004804B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
EA200200313A1 true EA200200313A1 (ru) 2002-08-29
EA004804B1 EA004804B1 (ru) 2004-08-26

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200313A EA004804B1 (ru) 1999-08-31 2000-08-29 Применение доцетаксела для лечения печеночно-клеточного рака

Country Status (34)

Country Link
US (2) US20030158249A1 (ru)
EP (1) EP1214061B1 (ru)
JP (1) JP4866522B2 (ru)
KR (1) KR100670416B1 (ru)
CN (1) CN1174748C (ru)
AT (1) ATE269700T1 (ru)
AU (1) AU777583B2 (ru)
BG (1) BG65913B1 (ru)
BR (1) BR0013625A (ru)
CA (1) CA2382294C (ru)
CZ (1) CZ301378B6 (ru)
DE (1) DE60011794T2 (ru)
DK (1) DK1214061T3 (ru)
EA (1) EA004804B1 (ru)
EE (1) EE05124B1 (ru)
ES (1) ES2218223T3 (ru)
GB (1) GB9920548D0 (ru)
HK (1) HK1048944B (ru)
HR (1) HRP20020171A2 (ru)
HU (1) HU228861B1 (ru)
IL (2) IL147489A0 (ru)
ME (1) ME00624B (ru)
MX (1) MXPA02002041A (ru)
NO (1) NO328527B1 (ru)
NZ (1) NZ517604A (ru)
PL (1) PL212612B1 (ru)
PT (1) PT1214061E (ru)
RS (1) RS50148B (ru)
SI (1) SI1214061T1 (ru)
SK (1) SK286378B6 (ru)
TW (1) TW589180B (ru)
UA (1) UA72927C2 (ru)
WO (1) WO2001015675A2 (ru)
ZA (1) ZA200201408B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
EP1947094A3 (en) * 2003-12-12 2009-02-18 Quiral Quimica Do Brasil Process for the preparation of taxane derivatives
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US7771751B2 (en) 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
CA2683712A1 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical compositions
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
MX341082B (es) * 2010-05-03 2016-08-08 Teikoku Pharma Usa Inc Formulaciones de pro-emulsion de taxano no acuosas y metodos para hacer y usar las mismas.
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20160250177A1 (en) * 2015-02-17 2016-09-01 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
WO1994016693A1 (en) * 1993-01-19 1994-08-04 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
US5801029A (en) * 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
AU1146099A (en) * 1997-09-18 1999-04-05 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
UA73092C2 (ru) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетки с энтеросолюбильным покрытием и способ их получения
JP2002533404A (ja) * 1998-12-23 2002-10-08 ジー・ディー・サール・アンド・カンパニー 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
KR20080007561A (ko) * 2005-12-13 2008-01-22 테바 파마슈티컬 인더스트리즈 리미티드 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법

Also Published As

Publication number Publication date
HK1048944A1 (en) 2003-04-25
BR0013625A (pt) 2002-05-14
SI1214061T1 (en) 2004-12-31
EE05124B1 (et) 2009-02-16
EP1214061B1 (en) 2004-06-23
DK1214061T3 (da) 2004-11-01
NO20020829D0 (no) 2002-02-20
ZA200201408B (en) 2003-07-30
MEP7809A (en) 2011-12-20
CN1174748C (zh) 2004-11-10
UA72927C2 (ru) 2005-05-16
PL353198A1 (en) 2003-11-03
CA2382294A1 (en) 2001-03-08
KR100670416B1 (ko) 2007-01-17
CN1372466A (zh) 2002-10-02
JP4866522B2 (ja) 2012-02-01
ES2218223T3 (es) 2004-11-16
HUP0203197A2 (hu) 2003-01-28
HU228861B1 (hu) 2013-06-28
BG106460A (bg) 2002-09-30
TW589180B (en) 2004-06-01
US20080045584A1 (en) 2008-02-21
PT1214061E (pt) 2004-09-30
HRP20020171A2 (en) 2004-02-29
ME00624B (me) 2011-12-20
CZ2002739A3 (cs) 2002-06-12
AU777583B2 (en) 2004-10-21
SK286378B6 (sk) 2008-08-05
HUP0203197A3 (en) 2005-01-28
NO328527B1 (no) 2010-03-08
WO2001015675A2 (en) 2001-03-08
IL147489A (en) 2006-06-11
PL212612B1 (pl) 2012-10-31
WO2001015675A3 (en) 2001-09-20
DE60011794T2 (de) 2005-07-14
DE60011794D1 (de) 2004-07-29
IL147489A0 (en) 2002-08-14
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
NO20020829L (no) 2002-02-20
RS50148B (sr) 2009-05-06
GB9920548D0 (en) 1999-11-03
CZ301378B6 (cs) 2010-02-03
YU11402A (sh) 2005-07-19
KR20020060166A (ko) 2002-07-16
NZ517604A (en) 2004-04-30
EA004804B1 (ru) 2004-08-26
HK1048944B (zh) 2005-04-22
US20030158249A1 (en) 2003-08-21
MXPA02002041A (es) 2002-08-20
SK2712002A3 (en) 2002-07-02
BG65913B1 (bg) 2010-05-31
CA2382294C (en) 2008-06-03
JP2003508427A (ja) 2003-03-04
EP1214061A2 (en) 2002-06-19
EE200200087A (et) 2003-04-15

Similar Documents

Publication Publication Date Title
EA200200313A1 (ru) Применение доцетаксела для лечения печеночно-клеточного рака
DE60318092D1 (de) Pharmazeutische zusammensetzung enthältend estetrolderivate und anwendung in der krebsbehandlung
BR0207378A (pt) Tratamento de câncer
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
CY1112946T1 (el) 4-υδροξυβενζομορφανια
DE60327994D1 (de) Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
ATE448232T1 (de) Substituierte heterozyklen
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
FR2869540B1 (fr) Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
CY1106319T1 (el) Τοπικη θepαπεια στη μασταλγια
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
SE0003476D0 (sv) Compounds
EA200501301A1 (ru) Ментоловые растворы лекарственных препаратов
DE60111614D1 (de) Taxan-derivate für die behandlung von krebs
TR200302193T4 (tr) Kombinasyon kemoterapisi.
ATE277622T1 (de) Arzneimittel enthaltend xenogene oligo- oder/und polyribonukleotide
ATE387913T1 (de) Xenogene oligo- oder/und polyribonukleotide als mittel zur behandlung von malignen tumoren
BR0113202A (pt) Compostos de trioxepano
DE50304524D1 (de) Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole
GR1003969B (el) Σταθερα φαρμακευτικα διαλυματα νιμεσουλιδης.
ECSP003812A (es) Compuestos de dihidropirimidina hererociclicos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU